Literature DB >> 18084739

[Fibrous dysplasia].

R Rödl1, C Götze.   

Abstract

Fibrous dysplasia is a tumorlike, benign lesion, caused by sporadic mutation during early embryogenesis. The skeletal involvement becomes increasingly visible during growth. The number and extent of dysplastic lesions increase until the age of 15. The polyostotic form is often associated with endocrine dysfunction, which should be diagnosed and treated early. Malignant transformation of fibrous dysplastic lesions is less than 1%; therefore, treatment or resection of the lesion itself is not necessary. The progress of the lesions during growth can lead to pain, fractures, and deformities. Bisphosphonates are effective for pain relief, but have no assured effect on the natural history of the disease. Fracture healing is not compromised by the disease. Conservative treatment with casts is therefore effective, especially for the upper limbs. The surgical approach with deformity correction and stabilization remains challenging particularly with regard to the proximal femur. Intramedullary devices should be preferred to plates, if possible.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18084739     DOI: 10.1007/s00132-007-1180-6

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  27 in total

1.  Fibular strut grafting for fibrous dysplasia of the femoral neck.

Authors:  D D Bryant; R E Grant; D Tang
Journal:  J Natl Med Assoc       Date:  1992-10       Impact factor: 1.798

2.  Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome.

Authors:  W F Schwindinger; C A Francomano; M A Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  Bisphosphonate therapy in fibrous dysplasia.

Authors:  J M Lane; S N Khan; W J O'Connor; M Nydick; J P Hommen; R Schneider; E Tomin; J Brand; J Curtin
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

4.  Telescoping intramedullary rodding with Bailey-Dubow nails for recurrent pathologic fractures in children without osteogenesis imperfecta.

Authors:  A T Laidlaw; R T Loder; R N Hensinger
Journal:  J Pediatr Orthop       Date:  1998 Jan-Feb       Impact factor: 2.324

5.  An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.

Authors:  Michael T Collins; Harvey Kushner; James C Reynolds; Caroline Chebli; Marilyn H Kelly; Anurag Gupta; Beth Brillante; Arabella I Leet; Mara Riminucci; Pamela Gehron Robey; Paolo Bianco; Shlomo Wientroub; Clara C Chen
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

6.  Multiple osteotomies with Zickel nail fixation for polyostotic fibrous dysplasia involving the proximal part of the femur.

Authors:  B H Freeman; E W Bray; L C Meyer
Journal:  J Bone Joint Surg Am       Date:  1987-06       Impact factor: 5.284

7.  Optic nerve decompression in cranial base fibrous dysplasia.

Authors:  F A Papay; L Morales; P Flaharty; S J Smith; R Anderson; J M WAlker; R S Hood; S Hardy
Journal:  J Craniofac Surg       Date:  1995-01       Impact factor: 1.046

8.  Surgical treatment of fibrous dysplasia of bone in McCune-Albright syndrome.

Authors:  E Ippolito; R Caterini; P Farsetti; V Potenza
Journal:  J Pediatr Endocrinol Metab       Date:  2002       Impact factor: 1.634

9.  Current approach to fibrous dysplasia of bone and McCune-Albright syndrome.

Authors:  Arabella I Leet; Michael T Collins
Journal:  J Child Orthop       Date:  2007-02-23       Impact factor: 1.548

10.  Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells.

Authors:  P Bianco; S A Kuznetsov; M Riminucci; L W Fisher; A M Spiegel; P G Robey
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

View more
  1 in total

1.  [Fibrous dysplasia].

Authors:  T Wirth
Journal:  Orthopade       Date:  2012-12       Impact factor: 1.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.